Automata, the lab automation company building fully integrated, AI-ready platforms for life sciences, today announced the close of a £33 million Series C funding round led by Dimension, with participation from Danaher Ventures, Tru Arrow Partners, Octopus Ventures and Entrepreneurs First. The round also includes a strategic investment partnership with Danaher Corporation, with Murali Venkatesan Ph.D. joining the Board of Directors. Automata is a lab automation company building fully integrated, AI-ready platforms for life sciences.
While artificial intelligence has transformed computational biology, physical lab work remains constrained by manual and fragmented workflows. Automata is addressing this gap by building a reference architecture for autonomous wet labs, combining modular robotics, orchestration software and unified data infrastructure to turn physical laboratories into programmable, repeatable systems. Its platform delivers gains in experimental throughput, reproducibility and resource efficiency across pharmaceutical, biotech and advanced research environments.
Automata counts five top pharmaceutical companies among its customers, with growth driven by repeat deployments and partnerships on large-scale automation projects. The new funding will be used to scale customer deployments globally, develop the next iteration of its data and closed-loop experimentation software platform, and expand global operations across engineering, product and customer success teams.
Through its strategic investment partnership, Danaher will integrate Automata's software with its portfolio of instruments, reagents and software, creating end-to-end solutions designed to accelerate discovery while optimising laboratory resources.
AI-first biology requires fundamentally different infrastructure. We're building the operating layer between AI models and the physical lab - enabling labs to run autonomously rather than as bespoke workshops. This funding allows us to scale that vision with customers who are already redefining what's possible in experimental science.
Scalable, software-defined lab operations are foundational to the AI wave in life science. Automata is building the technology stack to power modern labs and has emerged as a leader in this exciting new chapter for lab automation.
Advancements in robotics and automation, AI, compute, and instrumentation are powering the next wave of biological insights. We are proud to partner with Automata to accelerate customer workflows across drug discovery and development, foundational model development for biological systems, and automate advanced diagnostics.
